Increasing Understanding about the Role Biosimilar Agents in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 1 of 2)
Gary Lyman, MD, MPHIn September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung […] Read more
Interstitial Lung Abnormality, Interstitial Lung Disease, and Lung Cancer
Hiroto Hatabu, MD, PhD, FACR+more
As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with […] Read more
Pembrolizumab Is Active in Lung Cancer Brain Metastases
Sarah B. Goldberg, MDIn Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, […] Read more
Using Tumor Radiomic Features To Predict NSCLC Chemotherapy Response
Michelle Hershman, MD+more
IN REFERENCE TO: Khorrami M, Jain P, Bera K, et al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019;135:1-9. Read more
Growing Importance and Changing Dynamics: Social Media’s Ever-Changing Role in Thoracic Oncology
H. Jack West, MDAlthough some resist its gravitational pull, social media and especially Twitter are becoming an increasingly valuable tool in academic and community-based cancer care, with thoracic oncology helping set the pace […] Read more
A Lack of Standardization in Toxicity Reporting Leaves the Field Open to Misinformation
Emily A. Simons, MD, MPH+more
With many new lung cancer treatments approved through accelerated tracks based on early-phase (I/II) trial data, we have become increasingly aware of the lack of standards for disclosing toxicities when […] Read more
High Risk of Thromboembolic Events in Patients With NSCLC With ALK/ROS1 Fusions
Chuchu Shao, MD+more
The relationship between cancer and thromboembolic events as been widely studied since 1895. As we know, venous thromboembolism (VTE) is a well-recognized complication of malignancy, including pulmonary embolism (PE), deep-vein […] Read more
Remotely Monitoring Patients With Cancer Has Applicability During COVID-19 Pandemic and Beyond
Conni Bergmann KouryThe pandemic underscores unmet needs in critical care management and presents an opportunity for learning from patients with cancer. Read more
Approximately one-third of patients with NSCLC are diagnosed with stage III disease.1 Concurrent platinum-based chemotherapy with thoracic radiation (CRT) has been considered the cornerstone of treatment for patients with inoperable […] Read more
Checkpoint Inhibitors in SCLC: Putting the Most Novel Data in Context
Edgardo SantosTwo separate randomized phase III trials have established atezolizumab (IMpower1331 and durvalumab (CASPIAN2) as first-line treatments for extensive-stage (ES) SCLC in combination with chemotherapy followed by these same checkpoint inhibitors (CPIs) […] Read more